RxDoctor Payments Data

James Barnes, MD

Surgery · Shreveport, LANPI 1033158837

Payments from drug & device makers

What this record shows

This record is dominated by education: $21,655 of the $32,854 with a category attached, or 65.9%. Intuitive Surgical accounts for 93.4% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $10,397 and has fallen 50.8% since, to $5,118 in 2025. Among surgery clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$32,854in general payments, 2019–2025

Across 83 payments — averaging $395.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$31K
  • Midsouth Orthopedics Inc.$1K
  • Johnson & Johnson$377
  • Davol Inc.$125
  • Baxter Healthcare$125
  • Conmed Corporation$100
  • plus $273 from 5 others

What the payments were for

  • Travel & lodging$6,76121%
  • Food & beverage$4,36613%
  • Education$21,65566%
  • Gifts$480%
  • Other$250%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,854 in reported general payments places this provider in the 90th percentile of 381 surgery providers in Louisiana.

See all surgery providers in Louisiana

Medicare billing

Part B allowed, 2024
$129,634
Medicare patients
183
Services billed
914

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide13$11,839
Sucralfate84$5,264
Omeprazole122$1,094
Topiramate94$511
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen62$407
Cyanocobalamin InjectionCyanocobalamin (Vitamin B-12)23$339
Metronidazole18$205
Doxycycline Hyclate19$144
Ondansetron OdtOndansetron21$134
Meloxicam35$70

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$71$11,83913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 381 surgery providers in Louisiana.

Other surgery in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →